 | • レポートコード：MRC2Q12-19377 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、プリン作動性受容体拮抗薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 プリン作動性受容体拮抗薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 プリン作動性受容体拮抗薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 プリン作動性受容体拮抗薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのプリン作動性受容体拮抗薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のプリン作動性受容体拮抗薬の売上および2028年までの予測に焦点を当てています。 プリン作動性受容体拮抗薬のグローバル主要企業には、Sanofi、Bristol Myers Squibb、Apotex、Mylan、AstraZeneca、Chiesi Farmaceutici、Bayer、Zydus Cadila Healthcare、Sun Pharmaceutical、Huahai Pharmaceuticalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 プリン作動性受容体拮抗薬市場は、タイプとアプリケーションによって区分されます。世界のプリン作動性受容体拮抗薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 P2Y、P2X 【アプリケーション別セグメント】 心臓病、脳卒中、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - プリン作動性受容体拮抗薬製品概要 - タイプ別市場（P2Y、P2X） - アプリケーション別市場（心臓病、脳卒中、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のプリン作動性受容体拮抗薬販売量予測2017-2028 - 世界のプリン作動性受容体拮抗薬売上予測2017-2028 - プリン作動性受容体拮抗薬の地域別販売量 - プリン作動性受容体拮抗薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別プリン作動性受容体拮抗薬販売量 - 主要メーカー別プリン作動性受容体拮抗薬売上 - 主要メーカー別プリン作動性受容体拮抗薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（P2Y、P2X） - プリン作動性受容体拮抗薬のタイプ別販売量 - プリン作動性受容体拮抗薬のタイプ別売上 - プリン作動性受容体拮抗薬のタイプ別価格 ・アプリケーション別市場規模（心臓病、脳卒中、その他） - プリン作動性受容体拮抗薬のアプリケーション別販売量 - プリン作動性受容体拮抗薬のアプリケーション別売上 - プリン作動性受容体拮抗薬のアプリケーション別価格 ・北米市場 - 北米のプリン作動性受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のプリン作動性受容体拮抗薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのプリン作動性受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のプリン作動性受容体拮抗薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のプリン作動性受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のプリン作動性受容体拮抗薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のプリン作動性受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のプリン作動性受容体拮抗薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのプリン作動性受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のプリン作動性受容体拮抗薬市場規模（トルコ、サウジアラビア） ・企業情報 Sanofi、Bristol Myers Squibb、Apotex、Mylan、AstraZeneca、Chiesi Farmaceutici、Bayer、Zydus Cadila Healthcare、Sun Pharmaceutical、Huahai Pharmaceutical ・産業チェーン及び販売チャネル分析 - プリン作動性受容体拮抗薬の産業チェーン分析 - プリン作動性受容体拮抗薬の原材料 - プリン作動性受容体拮抗薬の生産プロセス - プリン作動性受容体拮抗薬の販売及びマーケティング - プリン作動性受容体拮抗薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - プリン作動性受容体拮抗薬の産業動向 - プリン作動性受容体拮抗薬のマーケットドライバー - プリン作動性受容体拮抗薬の課題 - プリン作動性受容体拮抗薬の阻害要因 ・主な調査結果 |
Drugs That Bind to Purine Receptors and Block Their Activation, Thereby Inhibiting Platelets, Are Mostly Used to Reduce the Risk of Heart Disease and Stroke in High-risk Groups.
Market Analysis and Insights: Global Purinergic Receptor Antagonists Market
The global Purinergic Receptor Antagonists market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, P2Y accounting for % of the Purinergic Receptor Antagonists global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Heart Disease segment is altered to an % CAGR throughout this forecast period.
China Purinergic Receptor Antagonists market size is valued at US$ million in 2021, while the North America and Europe Purinergic Receptor Antagonists are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Purinergic Receptor Antagonists landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Purinergic Receptor Antagonists market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Purinergic Receptor Antagonists market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Purinergic Receptor Antagonists market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Purinergic Receptor Antagonists market.
Global Purinergic Receptor Antagonists Scope and Market Size
Purinergic Receptor Antagonists market is segmented by players, region (country), by Receptor Type and by Application. Players, stakeholders, and other participants in the global Purinergic Receptor Antagonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Receptor Type and by Application for the period 2017-2028.
Segment by Receptor Type
P2Y
P2X
Segment by Application
Heart Disease
Stroke
Others
By Company
Sanofi
Bristol Myers Squibb
Apotex
Mylan
AstraZeneca
Chiesi Farmaceutici
Bayer
Zydus Cadila Healthcare
Sun Pharmaceutical
Huahai Pharmaceutical
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Receptor Type
1.2.1 Global Purinergic Receptor Antagonists Market Size Growth Rate by Receptor Type, 2017 VS 2021 VS 2028
1.2.2 P2Y
1.2.3 P2X
1.3 Market by Application
1.3.1 Global Purinergic Receptor Antagonists Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Heart Disease
1.3.3 Stroke
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Purinergic Receptor Antagonists Market Perspective (2017-2028)
2.2 Purinergic Receptor Antagonists Growth Trends by Region
2.2.1 Purinergic Receptor Antagonists Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Purinergic Receptor Antagonists Historic Market Size by Region (2017-2022)
2.2.3 Purinergic Receptor Antagonists Forecasted Market Size by Region (2023-2028)
2.3 Purinergic Receptor Antagonists Market Dynamics
2.3.1 Purinergic Receptor Antagonists Industry Trends
2.3.2 Purinergic Receptor Antagonists Market Drivers
2.3.3 Purinergic Receptor Antagonists Market Challenges
2.3.4 Purinergic Receptor Antagonists Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Purinergic Receptor Antagonists Players by Revenue
3.1.1 Global Top Purinergic Receptor Antagonists Players by Revenue (2017-2022)
3.1.2 Global Purinergic Receptor Antagonists Revenue Market Share by Players (2017-2022)
3.2 Global Purinergic Receptor Antagonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Purinergic Receptor Antagonists Revenue
3.4 Global Purinergic Receptor Antagonists Market Concentration Ratio
3.4.1 Global Purinergic Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Purinergic Receptor Antagonists Revenue in 2021
3.5 Purinergic Receptor Antagonists Key Players Head office and Area Served
3.6 Key Players Purinergic Receptor Antagonists Product Solution and Service
3.7 Date of Enter into Purinergic Receptor Antagonists Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Purinergic Receptor Antagonists Breakdown Data by Receptor Type
4.1 Global Purinergic Receptor Antagonists Historic Market Size by Receptor Type (2017-2022)
4.2 Global Purinergic Receptor Antagonists Forecasted Market Size by Receptor Type (2023-2028)
5 Purinergic Receptor Antagonists Breakdown Data by Application
5.1 Global Purinergic Receptor Antagonists Historic Market Size by Application (2017-2022)
5.2 Global Purinergic Receptor Antagonists Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Purinergic Receptor Antagonists Market Size (2017-2028)
6.2 North America Purinergic Receptor Antagonists Market Size by Receptor Type
6.2.1 North America Purinergic Receptor Antagonists Market Size by Receptor Type (2017-2022)
6.2.2 North America Purinergic Receptor Antagonists Market Size by Receptor Type (2023-2028)
6.2.3 North America Purinergic Receptor Antagonists Market Share by Receptor Type (2017-2028)
6.3 North America Purinergic Receptor Antagonists Market Size by Application
6.3.1 North America Purinergic Receptor Antagonists Market Size by Application (2017-2022)
6.3.2 North America Purinergic Receptor Antagonists Market Size by Application (2023-2028)
6.3.3 North America Purinergic Receptor Antagonists Market Share by Application (2017-2028)
6.4 North America Purinergic Receptor Antagonists Market Size by Country
6.4.1 North America Purinergic Receptor Antagonists Market Size by Country (2017-2022)
6.4.2 North America Purinergic Receptor Antagonists Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Purinergic Receptor Antagonists Market Size (2017-2028)
7.2 Europe Purinergic Receptor Antagonists Market Size by Receptor Type
7.2.1 Europe Purinergic Receptor Antagonists Market Size by Receptor Type (2017-2022)
7.2.2 Europe Purinergic Receptor Antagonists Market Size by Receptor Type (2023-2028)
7.2.3 Europe Purinergic Receptor Antagonists Market Share by Receptor Type (2017-2028)
7.3 Europe Purinergic Receptor Antagonists Market Size by Application
7.3.1 Europe Purinergic Receptor Antagonists Market Size by Application (2017-2022)
7.3.2 Europe Purinergic Receptor Antagonists Market Size by Application (2023-2028)
7.3.3 Europe Purinergic Receptor Antagonists Market Share by Application (2017-2028)
7.4 Europe Purinergic Receptor Antagonists Market Size by Country
7.4.1 Europe Purinergic Receptor Antagonists Market Size by Country (2017-2022)
7.4.2 Europe Purinergic Receptor Antagonists Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Purinergic Receptor Antagonists Market Size (2017-2028)
8.2 Asia-Pacific Purinergic Receptor Antagonists Market Size by Receptor Type
8.2.1 Asia-Pacific Purinergic Receptor Antagonists Market Size by Receptor Type (2017-2022)
8.2.2 Asia-Pacific Purinergic Receptor Antagonists Market Size by Receptor Type (2023-2028)
8.2.3 Asia-Pacific Purinergic Receptor Antagonists Market Share by Receptor Type (2017-2028)
8.3 Asia-Pacific Purinergic Receptor Antagonists Market Size by Application
8.3.1 Asia-Pacific Purinergic Receptor Antagonists Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Purinergic Receptor Antagonists Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Purinergic Receptor Antagonists Market Share by Application (2017-2028)
8.4 Asia-Pacific Purinergic Receptor Antagonists Market Size by Region
8.4.1 Asia-Pacific Purinergic Receptor Antagonists Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Purinergic Receptor Antagonists Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Purinergic Receptor Antagonists Market Size (2017-2028)
9.2 Latin America Purinergic Receptor Antagonists Market Size by Receptor Type
9.2.1 Latin America Purinergic Receptor Antagonists Market Size by Receptor Type (2017-2022)
9.2.2 Latin America Purinergic Receptor Antagonists Market Size by Receptor Type (2023-2028)
9.2.3 Latin America Purinergic Receptor Antagonists Market Share by Receptor Type (2017-2028)
9.3 Latin America Purinergic Receptor Antagonists Market Size by Application
9.3.1 Latin America Purinergic Receptor Antagonists Market Size by Application (2017-2022)
9.3.2 Latin America Purinergic Receptor Antagonists Market Size by Application (2023-2028)
9.3.3 Latin America Purinergic Receptor Antagonists Market Share by Application (2017-2028)
9.4 Latin America Purinergic Receptor Antagonists Market Size by Country
9.4.1 Latin America Purinergic Receptor Antagonists Market Size by Country (2017-2022)
9.4.2 Latin America Purinergic Receptor Antagonists Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Purinergic Receptor Antagonists Market Size (2017-2028)
10.2 Middle East & Africa Purinergic Receptor Antagonists Market Size by Receptor Type
10.2.1 Middle East & Africa Purinergic Receptor Antagonists Market Size by Receptor Type (2017-2022)
10.2.2 Middle East & Africa Purinergic Receptor Antagonists Market Size by Receptor Type (2023-2028)
10.2.3 Middle East & Africa Purinergic Receptor Antagonists Market Share by Receptor Type (2017-2028)
10.3 Middle East & Africa Purinergic Receptor Antagonists Market Size by Application
10.3.1 Middle East & Africa Purinergic Receptor Antagonists Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Purinergic Receptor Antagonists Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Purinergic Receptor Antagonists Market Share by Application (2017-2028)
10.4 Middle East & Africa Purinergic Receptor Antagonists Market Size by Country
10.4.1 Middle East & Africa Purinergic Receptor Antagonists Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Purinergic Receptor Antagonists Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Purinergic Receptor Antagonists Introduction
11.1.4 Sanofi Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.1.5 Sanofi Recent Developments
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Purinergic Receptor Antagonists Introduction
11.2.4 Bristol Myers Squibb Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.2.5 Bristol Myers Squibb Recent Developments
11.3 Apotex
11.3.1 Apotex Company Details
11.3.2 Apotex Business Overview
11.3.3 Apotex Purinergic Receptor Antagonists Introduction
11.3.4 Apotex Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.3.5 Apotex Recent Developments
11.4 Mylan
11.4.1 Mylan Company Details
11.4.2 Mylan Business Overview
11.4.3 Mylan Purinergic Receptor Antagonists Introduction
11.4.4 Mylan Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.4.5 Mylan Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Purinergic Receptor Antagonists Introduction
11.5.4 AstraZeneca Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.5.5 AstraZeneca Recent Developments
11.6 Chiesi Farmaceutici
11.6.1 Chiesi Farmaceutici Company Details
11.6.2 Chiesi Farmaceutici Business Overview
11.6.3 Chiesi Farmaceutici Purinergic Receptor Antagonists Introduction
11.6.4 Chiesi Farmaceutici Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.6.5 Chiesi Farmaceutici Recent Developments
11.7 Bayer
11.7.1 Bayer Company Details
11.7.2 Bayer Business Overview
11.7.3 Bayer Purinergic Receptor Antagonists Introduction
11.7.4 Bayer Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.7.5 Bayer Recent Developments
11.8 Zydus Cadila Healthcare
11.8.1 Zydus Cadila Healthcare Company Details
11.8.2 Zydus Cadila Healthcare Business Overview
11.8.3 Zydus Cadila Healthcare Purinergic Receptor Antagonists Introduction
11.8.4 Zydus Cadila Healthcare Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.8.5 Zydus Cadila Healthcare Recent Developments
11.9 Sun Pharmaceutical
11.9.1 Sun Pharmaceutical Company Details
11.9.2 Sun Pharmaceutical Business Overview
11.9.3 Sun Pharmaceutical Purinergic Receptor Antagonists Introduction
11.9.4 Sun Pharmaceutical Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.9.5 Sun Pharmaceutical Recent Developments
11.10 Huahai Pharmaceutical
11.10.1 Huahai Pharmaceutical Company Details
11.10.2 Huahai Pharmaceutical Business Overview
11.10.3 Huahai Pharmaceutical Purinergic Receptor Antagonists Introduction
11.10.4 Huahai Pharmaceutical Revenue in Purinergic Receptor Antagonists Business (2017-2022)
11.10.5 Huahai Pharmaceutical Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer